TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39193419

Group type: EXPERIMENTAL
Intervention: Omalizumab; specific dosage and duration not mentioned.
Number of subjects: 0
Study: 39193463

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) in addition to conventional medication, 12 EA sessions over 6 weeks.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Waiting-list group receiving only conventional medication.
Number of subjects: 104
Study: 39193596

Group type: COMPARATOR
Intervention: New radar device for diagnosing OSA
Number of subjects: 0
Study: 39193655

Group type: EXPERIMENTAL
Intervention: 1 mcg/kg dexmedetomidine
Number of subjects: 67

Group type: COMPARATOR
Intervention: 0.25 mcg/kg dexmedetomidine
Number of subjects: 67

Group type: COMPARATOR
Intervention: 0.5 mcg/kg dexmedetomidine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 39193706

Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE) for 6 weeks (20h-fasting/4h-eating)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard lifestyle
Number of subjects: 39
Study: 39193709

Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan
Number of subjects: 4822

Group type: COMPARATOR
Intervention: valsartan
Number of subjects: 4822
Study: 39193773

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39194012

Group type: EXPERIMENTAL
Intervention: Internet-delivered exposure-based cognitive behavior therapy (ECBT) for 12 weeks
Number of subjects: 309
Study: 39194024

Group type: EXPERIMENTAL
Intervention: Watchful waiting strategy (no antimicrobial administration for ventilator-associated tracheobronchitis, antimicrobials prescribed only for ventilator-associated pneumonia, sepsis, septic shock, or another infectious diagnosis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine antimicrobial treatment strategy for seven days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Watchful waiting strategy
Number of subjects: 0
Study: 39194097

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bilevel positive airway pressure
Number of subjects: 50
Study: 39194206

Group type: EXPERIMENTAL
Intervention: iAST's first three antibiotic recommendations
Number of subjects: 325

Group type: COMPARATOR
Intervention: Doctor's prescribed antibiotics
Number of subjects: 325
Study: 39195506

Group type: EXPERIMENTAL
Intervention: Oligomalt (50 g)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Maltodextrin (50 g)
Number of subjects: 15
Study: 39196095

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39196191

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39196551

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (fish oil) 2.4 g per day until 1 week post partum
Number of subjects: 736

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (fish oil)
Number of subjects: 736
Study: 39196580

Group type: EXPERIMENTAL
Intervention: Funnel-shaped intraperitoneal mesh
Number of subjects: 143

Group type: COMPARATOR
Intervention: No mesh (control)
Number of subjects: 143
Study: 39196631

Group type: EXPERIMENTAL
Intervention: School safety interventions in schools that have experienced a school shooting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Schools that have experienced a school shooting
Number of subjects: 12

Group type: COMPARATOR
Intervention: Schools that have never experienced a school shooting
Number of subjects: 12
Study: 39196651

Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 0
Study: 39196693

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 605

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 605
Study: 39196713

Group type: EXPERIMENTAL
Intervention: Early coronary revascularization (<24 h)
Number of subjects: 2343

Group type: COMPARATOR
Intervention: Initial conservative strategy
Number of subjects: 2343

Group type: EXPERIMENTAL
Intervention: Diabetes in elderly patients
Number of subjects: 2343

Group type: EXPERIMENTAL
Intervention: Diabetes in younger patients
Number of subjects: 2343
Study: 39196855

Group type: EXPERIMENTAL
Intervention: Palliative Care Educators (PCEs) integrated into existing hospital wards
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Palliative Care Educators (PCEs)
Number of subjects: 24
Study: 39197067

Group type: EXPERIMENTAL
Intervention: N-TEC implantation
Number of subjects: 5
Study: 39197072

Group type: EXPERIMENTAL
Intervention: idecabtagene vicleucel (ide-cel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: standard regimens (SRs)
Number of subjects: 0
Study: 39197113

Group type: EXPERIMENTAL
Intervention: Ubrogepant 100 mg
Number of subjects: 518

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 518
Study: 39197275

Group type: EXPERIMENTAL
Intervention: Couple-based health education, home visits, and information flyers along with usual care
Number of subjects: 320

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 320
Study: 39197510

Group type: EXPERIMENTAL
Intervention: Ensifentrine (3 mg tid for 24 weeks)
Number of subjects: 1549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1549
Study: 39197976

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4614

Group type: EXPERIMENTAL
Intervention: Vitamin K antagonist (VKA)
Number of subjects: 4614

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4614

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4614
Study: 39198005

Group type: EXPERIMENTAL
Intervention: UK embryologists
Number of subjects: 740

Group type: COMPARATOR
Intervention: US embryologists
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Both UK and US embryologists
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 740
Study: 39198011

Group type: EXPERIMENTAL
Intervention: Oil-based iodinated contrast media during HSG
Number of subjects: 69

Group type: COMPARATOR
Intervention: Water-based iodinated contrast media during HSG
Number of subjects: 69
Study: 39198799

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg via HandiHaler
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (untreated COPD patients and healthy volunteers)
Number of subjects: 36
Study: 39198824

Group type: EXPERIMENTAL
Intervention: NRTS + AAR
Number of subjects: 1200

Group type: COMPARATOR
Intervention: AAR alone
Number of subjects: 1200
Study: 39198860

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 39198868

Group type: EXPERIMENTAL
Intervention: Question Prompt List (QPL)
Number of subjects: 110
Study: 39198875

Group type: EXPERIMENTAL
Intervention: ROM-DB (upper limb elevations with simultaneous deep breathing)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ROM (upper limb elevations without deep breathing)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: ROM-DB
Number of subjects: 22

Group type: COMPARATOR
Intervention: ROM
Number of subjects: 22
Study: 39198900

Group type: EXPERIMENTAL
Intervention: Nurse-led, interprofessional family support intervention (FSI)
Number of subjects: 896

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 896
Study: 39198915

Group type: EXPERIMENTAL
Intervention: Community Model (community intervention delivered by volunteers)
Number of subjects: 79488

Group type: COMPARATOR
Intervention: Facility Model (standard care with HAP)
Number of subjects: 79488

Group type: EXPERIMENTAL
Intervention: Community Model
Number of subjects: 79488
Study: 39199367

Group type: EXPERIMENTAL
Intervention: Elevated IL-10 levels
Number of subjects: 1002

Group type: COMPARATOR
Intervention: IL-10 haplotypes
Number of subjects: 1002
Study: 39199651

Group type: EXPERIMENTAL
Intervention: Machine Learning methods (random survival forests, survival neural networks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cox proportional hazard model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extended Cox model with time-varying effects
Number of subjects: 0
Study: 39199994

Group type: EXPERIMENTAL
Intervention: RHB-104 (triple antimicrobial therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39200725

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 39201126

Group type: EXPERIMENTAL
Intervention: SEMG biofeedback-assisted core strengthening exercises with kinesiotaping
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Core strengthening exercises with kinesiotaping
Number of subjects: 24

Group type: COMPARATOR
Intervention: Non-assisted exercises
Number of subjects: 24
Study: 39201278

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39202082

Group type: EXPERIMENTAL
Intervention: Physical Therapy sessions of goal-directed and task-specific training (30 sessions, 3 per week for 10 weeks)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual Physical Therapy treatment
Number of subjects: 62
Study: 39202235

Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography-Angiography (OCT-A) assessment in CPA group
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Surgical decompression of the optic chiasm in CPA patients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Preoperative parameters in CPA group
Number of subjects: 38
Study: 39202581

Group type: EXPERIMENTAL
Intervention: Combined Low Dose of Human Chorionic Gonadotropin (HCG) and Clomiphene Citrate (CC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued Clomiphene Citrate (CC)
Number of subjects: 0
Study: 39203915

Group type: EXPERIMENTAL
Intervention: Fermented Soybean (FSB) Supplementation (1 g once daily for 12 weeks)
Number of subjects: 110
Study: 39204009

Group type: COMPARATOR
Intervention: AZD1222 (ChAdOx1 nCoV-19)
Number of subjects: 32450
Study: 39206182

Group type: EXPERIMENTAL
Intervention: Individual randomized physical activity-promoting intervention
Number of subjects: 0
Study: 39206189

Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: AS04/Alum
Number of subjects: 0
Study: 39206260

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 39206307

Group type: EXPERIMENTAL
Intervention: A2 β-casein infant formula with high sn-2 palmitate and casein phosphopeptides
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39206389

Group type: EXPERIMENTAL
Intervention: Semaglutide (GLP-1 agonist)
Number of subjects: 0
Study: 39206494

Group type: EXPERIMENTAL
Intervention: PEEK retainer
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dead-soft coaxial fixed retainer (DSC)
Number of subjects: 46
Study: 39206547

Group type: EXPERIMENTAL
Intervention: Proteomic summary composite
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Protein cluster with caspase-3
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Protein cluster with tumor necrosis factor receptor 1
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Protein cluster with protein C
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Protein clusters at baseline
Number of subjects: 763
Study: 39206549

Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (threshold, 10 g/dL)
Number of subjects: 3415

Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (threshold, 7-8 g/dL)
Number of subjects: 3415
Study: 39206728

Group type: EXPERIMENTAL
Intervention: Clonal Hematopoiesis (CH)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Non-Clonal Hematopoiesis (non-CH)
Number of subjects: 314
Study: 39207239

Group type: EXPERIMENTAL
Intervention: Epinephrine delivered via metered-dose inhalation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular injection of epinephrine
Number of subjects: 0
Study: 39207344

Group type: EXPERIMENTAL
Intervention: Triptans
Number of subjects: 3518

Group type: COMPARATOR
Intervention: Nontriptan treatments
Number of subjects: 3518
Study: 39207396

Group type: EXPERIMENTAL
Intervention: Cocaine demand
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anhedonia
Number of subjects: 0
Study: 39207422

Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity intervention involving step tracking and psychoeducational materials
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water tracking (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 0
Study: 39207423

Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39207432

Group type: EXPERIMENTAL
Intervention: MOVED condition (moral elevation intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 39207550

Group type: EXPERIMENTAL
Intervention: Polypropylene onlay mesh
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (no polypropylene onlay mesh)
Number of subjects: 116
Study: 39207839

Group type: EXPERIMENTAL
Intervention: Inpatient nipple stimulation therapy via an electric breast pump
Number of subjects: 988

Group type: COMPARATOR
Intervention: Immediate synthetic oxytocin infusion without nipple stimulation
Number of subjects: 988
Study: 39207912

Group type: EXPERIMENTAL
Intervention: Chronic Care Management With Wearable Devices (mPAP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 50
Study: 39208136

Group type: EXPERIMENTAL
Intervention: Global exercise training
Number of subjects: 70

Group type: COMPARATOR
Intervention: Handwriting upper limb exercise training
Number of subjects: 70
Study: 39208192

Group type: EXPERIMENTAL
Intervention: Caregiver study visits including the Last Month of Life survey, study-specific questions, and a semi-structured interview.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Caregiver experiences during the last month of life.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Access to information about DLB, support, and hospice care.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Hospice care utilization.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Communication, care coordination, quality care, and caregiver education in hospice.
Number of subjects: 50
Study: 39208325

Group type: EXPERIMENTAL
Intervention: Text message invitation
Number of subjects: 10844

Group type: COMPARATOR
Intervention: Letter invitation (control)
Number of subjects: 10844
Study: 39208372

Group type: EXPERIMENTAL
Intervention: Blocking of [specific intervention not provided]
Number of subjects: 7
Study: 39208374

Group type: EXPERIMENTAL
Intervention: Targeted methylation-based MCED test
Number of subjects: 420
Study: 39208379

Group type: EXPERIMENTAL
Intervention: Tarlatamab
Number of subjects: 0
Study: 39208403

Group type: EXPERIMENTAL
Intervention: NANO-LM consensus scorecard for clinical assessment
Number of subjects: 0
Study: 39208412

Group type: EXPERIMENTAL
Intervention: SSMW only
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: SSMW+coach
Number of subjects: 456

Group type: COMPARATOR
Intervention: UWC
Number of subjects: 456
Study: 39208425

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based telehealth intervention including pretest and posttest live AV conferencing sessions, home specimen self-collection for bacterial STI screening.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based telehealth intervention.
Number of subjects: 75
Study: 39208489

Group type: EXPERIMENTAL
Intervention: Ipilimumab/nivolumab followed by nivolumab maintenance
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Reinduction with ipilimumab/nivolumab
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Treatment-free observation period
Number of subjects: 9
Study: 39208520

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 45
Study: 39208776

Group type: EXPERIMENTAL
Intervention: Hemodynamic optimization according to the study protocol (systolic BP targets: 140-160 mm Hg for mTICI = 2b; 100-140 mm Hg for mTICI = 2c/3) applied within the first 72 hours.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current BP management guidelines (≤180/105 mm Hg).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hemodynamic optimization protocol (systolic BP targets)
Number of subjects: 0
Study: 39208825

Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg per month intravenously or 200 mg per week subcutaneously)
Number of subjects: 3086

Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 3086
Study: 39208836

Group type: EXPERIMENTAL
Intervention: Elexacaftor-tezacaftor-ivacaftor (ETI) treatment
Number of subjects: 20
Study: 39208856

Group type: EXPERIMENTAL
Intervention: pTVG-HP, 100-1500 µg, administered over 12 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: pTVG-HP, 100 µg with different schedules of administration over 1 year
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Detection of T-cells specific for the PAP target antigen
Number of subjects: 39
Study: 39208947

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA) only
Number of subjects: 107
Study: 39209068

Group type: EXPERIMENTAL
Intervention: Dupilumab 100/200 mg every 2 weeks
Number of subjects: 347

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study: 39209113

Group type: EXPERIMENTAL
Intervention: PDS 100 mg/mL with fixed refill-exchanges every 24 weeks (Q24W)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab 0.5-mg injections
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: PDS 100 mg/mL
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: Ladder-to-Portal previous monthly ranibizumab patients
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: All-PDS safety population
Number of subjects: 555
Study: 39209155

Group type: EXPERIMENTAL
Intervention: Leucine intake at 7 different levels over a 3-day period after 2 days of preadaptation to adequate protein intake (1.0 g⋅kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Leucine intake
Number of subjects: 10
Study: 39209187

Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg once daily
Number of subjects: 208

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 208
Study: 39209203

Group type: EXPERIMENTAL
Intervention: 10 g gluten per day
Number of subjects: 13

Group type: COMPARATOR
Intervention: 3 g gluten per day
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Proteome scores at day 15
Number of subjects: 13
Study: 39209369

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment for 12 weeks
Number of subjects: 136
Study: 39209438

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Medical treatment (MT)
Number of subjects: 52
Study: 39209452

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy with camrelizumab, nab-paclitaxel, and carboplatin (Cohort 1, 66 patients)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Various immune checkpoint inhibitors with (nab-)paclitaxel and platinum-based chemotherapy (Cohort 2, 48 patients)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment of toripalimab with chemotherapy (Cohort 3, 27 patients)
Number of subjects: 141
Study: 39209495

Group type: EXPERIMENTAL
Intervention: High-exchange SBUF (H-SBUF) during CPB
Number of subjects: 96

Group type: COMPARATOR
Intervention: Low-exchange SBUF (L-SBUF) during CPB
Number of subjects: 96
Study: 39209498

Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case-ICU intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 39209524

Group type: EXPERIMENTAL
Intervention: Combined online and onsite implementation strategy (coach workshop and HSP support)
Number of subjects: 945

Group type: COMPARATOR
Intervention: Online-only strategy (control group)
Number of subjects: 945
Study: 39209730

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine plus dexamethasone 0.1 mg/kg (DEX0.1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine plus dexamethasone 0.05 mg/kg (DEX0.05)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 0.5% ropivacaine with saline (control)
Number of subjects: 90
Study: 39209770

Group type: EXPERIMENTAL
Intervention: Self-care in patients with IBD
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Caregiver contributions to self-care
Number of subjects: 250
Study: 39209778

Group type: EXPERIMENTAL
Intervention: Antihypertensive deprescribing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39209781

Group type: EXPERIMENTAL
Intervention: methylprednisolone (62.5 mg/mL)
Number of subjects: 148

Group type: COMPARATOR
Intervention: placebo (sodium chloride 0.9%)
Number of subjects: 148
Study: 39209782

Group type: EXPERIMENTAL
Intervention: Sabatolimab 800 mg every 4 weeks plus spartalizumab 400 mg every 4 weeks until unacceptable toxicity, disease progression and/or treatment discontinuation.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Sabatolimab plus spartalizumab
Number of subjects: 33
Study: 39209823

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50-µg booster dose)
Number of subjects: 29035

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (primary vaccination)
Number of subjects: 29035

Group type: COMPARATOR
Intervention: Placebo-mRNA-1273 (control group)
Number of subjects: 29035

Group type: EXPERIMENTAL
Intervention: mRNA-1273 (primary vaccination and boosting)
Number of subjects: 29035
Study: 39209968

Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MoCA
Number of subjects: 0
Study: 39210194

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radio-chemotherapy (Group 1, 25 cases)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No neoadjuvant treatment (Group 2, 28 cases)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radio-chemotherapy (Group 1)
Number of subjects: 53

Group type: COMPARATOR
Intervention: No neoadjuvant treatment (Group 2)
Number of subjects: 53